Annovis Bio, Inc.

11/03/2023

On October 24th, Dr. Gregory Petsko, Ph.D. of Harvard Medical School and member of Annovis Bio's Scientific Advisory Board was awarded the National Medal of Science by President Joe Biden in a ceremony held in the East Room of the White House. The National Medal of Science is the highest honor the United States can confer on a scientist. Join us in congratulating Dr. Petsko!

10/24/2023

Annovis Bio, Inc. presented two posters at the 2023 Clinical Trials on Alzheimer's Disease conference in Boston, Massachusetts. Read the full news release:

BERWYN, Pa.--(BUSINESS WIRE)-- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on...

10/19/2023

for a live webcast today at 8:30 AM ET where Annovis Bio, Inc. will present at the 2023 ThinkEquity Conference in New York City.

Watch via the link:

10/11/2023

Annovis Bio, Inc. is excited to attend and present at the 8th Annual Dawson James Securities Investor Conference in Jupiter, Florida.

09/29/2023

Over 111 countries participated in in 2022 through advocacy, fundraising, events, and more. In 2023, we hope to see that number grow as we continue to raise awareness and research treatment.

09/26/2023

While their motion may be impacted, most individuals with Parkinson’s Disease have high cognitive function. We must change perception while we work towards treatment.

US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.

09/21/2023

Today is World Alzheimer's Awareness Day. According to Alzheimer's Disease International, 1 in 4 people think there is nothing we can do to prevent Alzheimer’s Disease. Let’s challenge the stigma around Alzheimer's Disease as we work for a treatment.

09/14/2023

September is World Alzheimer’s Month. As the number of people living with Alzheimer’s Disease is set to triple by 2050, this year’s focus is ‘never too early, never too late.’ Greater awareness and education lead to earlier intervention and treatment.

09/11/2023

We are excited to share that we have reached the halfway mark in our goal for patient enrollment in our phase II/III study of buntanetap, a potential treatment for Alzheimer's disease. Currently, the study has enrolled 166 patients, and we are continuing to make remarkable progress in recruiting additional participants.

Neurodegenerative Disorders

08/29/2023

While the technology described is still early, it points toward potential earlier monitoring and treatment. We're encouraged to see discussion around the connection between all neurodegenerative diseases, which aligns with our approach to drug development.

People with high chance of developing disease could be warned up to seven years before symptoms appear, research indicates

08/25/2023

Congratulations to our Founder and CEO Dr. Maria Maccecchini!

08/16/2023

Join us in congratulating Melissa Gaines on her promotion to Senior VP, Clinical Operations!